Continuous improvement is critical to the success of organisations in any industry. For pharma companies, constant improvement is likely imperative to survival. The pharmaceutical industry is under intense pressure to meet strict regulatory requirements and pricing pressures while evolving to meet changing customer expectations.
Pharmaceutical manufacturers must meet regulatory requirements for adherence to Current Good Manufacturing Practices (CGMP) to supply the US market. There is now a real focus on improving quality and the tightening up of regulations because quality problems trigger supply disruptions and shortages. Importantly, inline cleaniness testing between batches is a costly 5-day downtime for manufacturers.
GreyScan® PTD-1 has been extensively tested in the university lab and is now poised to go into the field with global giant, Pfizer. Greyscan is in the position to replace the equipment currently used for quality control in manufacturing.
GreyScan PTD-1 can provide on-the-spot quality management inline cleanliness checks/monitoring between batches of drugs, alleviating the current 5-day downtime, resulting in significant cost savings for pharmaceutical manufacturers.
GreyScan will launch PTD-1 at the end of 2021 and establish a footprint in pharma companies to start looking at final product quality control, the PTD-2.